Pramodini B. Kale-Pradhan Pharm.D.

Pramodini B. Kale-Pradhan Pharm.D.


Professor (Clinical)


Pharmacy Practice

Office Location

EACPHS, Room 4132




Pramodini B. Kale-Pradhan Pharm.D.

Degrees and Certifications

  • Doctor of Pharmacy, Philadelphia College of Pharmacy and Science, Philadelphia, PA
  • Bachelor of Science in Pharmacy, University of Wisconsin-Madision, Madision, WI
  • Advanced Resident in Infectious Diseases and Surgery, The University of Illinois at Chicago-College of Pharmacy
  • Fellow in Infectious Diseases and Surgery, The University of Illinois at Chicago-College of Pharmacy

Positions and Employment

  • 2011-present, Professor (Clinical), Department of Pharmacy Practice
  • 2007-present, Clinical Specialist - Infectious Diseases, St. John Hospital and Medical Center, Detroit, MI
  • 2000-2010, Associate Professor (Clinical) Department of Pharmacy Practice
  • 1991-2007, Clinical Specialist – Surgical Intensive Care, St. John Hospital and Medical Center, Detroit, MI
  • 1991-2000, Assistant Professor (Clinical), Department of Pharmacy Practice

Awards and Honors

  • College of Pharmacy and Allied Health Professions, Excellence in Teaching Award, 2001
  • Externship Preceptor of the Year, 2001
  • Preceptor of the Year Award, Southeastern Michigan Society of Hospital Pharmacists, 2000
  • Preceptor of the Year Award, Hoffman LaRoche Hospital, 1998
  • Preceptor of the Year Award, Southeastern Michigan Society of Hospital Pharmacists, 1992-1993

Professional Memberships

  • Rho Chi Honor Society
  • Infectious Disease Society of America, 2007-present
  • Society of Critical Care Medicine, 2000-present
  • American Association of Colleges of Pharmacy, 1992-present
  • Southeastern Michigan Society of Hospital Pharmacists, 1991-present
  • American Colleges of Clinical Pharmacy, 1990-present
  • American Society of Hospital Pharmacists, 1982-present

Areas of Expertise

  • Gastroenterology
  • Infectious diseases

Recent Publications

Selected publications

  1. McConachie SM, Wilhelm SM, Bhargava A, Kale-Pradhan PB. Biologic-Induced Infections in Inflammatory Bowel Disease: The TNF-α Antagonists. Ann Pharmacother. 2018 Jan 1:1060028018754896. doi: 10.1177/1060028018754896.
  2. Giuliano CA, Binienda J, Kale-Pradhan PB and Fakih M. "I Never Would Have Caught That Before": Pharmacist Perceptions of Using Clinical Decision Support for Antimicrobial Stewardship in the United States. Qual Health Res. 2018 Jan 1:1049732317750863. doi: 10.1177/1049732317750863.
  3. Lipari M, Smith AL, Wilhelm SM and Kale-Pradhan PB. Adherence to GOLD Guidelines in the Inpatient COPD Population. J Pharm Pract. 2018 Feb;31(1):29-33. doi: 10.1177/0897190017696949. Epub 2017 Mar 6.
  4. Nickerson M, Bhargava A, Kale-Pradhan PB. Daptomycin-associated eosinophilic pneumonia with rechallenge: a case report. Int J Clin Pharmacol Ther. 2017 Apr 13. doi: 10.5414/CP202952.
  5. McConachie S, Wilhelm SM, Kale-Pradhan PB. Biosimilars in Inflammatory Bowel Disease - Accumulating Clinical Evidence. Expert Rev Clin Pharmacol. 2017;10(4):391-400. doi: 10.1080/17512433.2017.1283983. PMID: 28095262
  6. Kale-Pradhan PB and Wilhelm SM. Prebiotics and Probiotics. In Handbook of Non-Prescription Drugs – An Interactive Approach to Self Care 19th Ed., (Invited Chapter) 2017 –
  7. Giuliano CA, Patel CR, Kale-Pradhan PB. Is the Combination of Piperacillin-Tazobactam and Vancomycin Associated with Development of Acute Kidney Injury? A Meta-analysis. Pharmacotherapy. 2016 Dec;36(12):1217-1228. doi: 10.1002/phar.1851.
  8. McConachie SM, Wilhelm SM, Kale-Pradhan PB. New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir. Expert Rev Clin Pharmacol. 2016 Feb;9(2):287-302. doi: 10.1586/17512433.2016.1129272. Epub 2016 Jan 8.
  9. Kale-Pradhan PB, Mihaescu A, Wilhelm SM. Fluoroquinolone Sequential Therapy for Helicobacter pylori: A Meta-analysis. Pharmacotherapy. 2015;35(8):719-730. doi: 10.1002/phar.1614. [Epub ahead of print]
  10. Lipari M and Kale-Pradhan PB. Vulnerable COPD patients with comorbidities: The role of rofumilast Therapeutics and Clinical Risk Management. 2014;10:969-976.
  11. Wilhelm SM, Kale-Pradhan PB. Effects of proton pump inhibitors on vitamin B12. Maturitas. 2014 79:1-2. doi: 10.1016/j.maturitas.2014.06.005.
  12. Wilhelm SM, Young J, and Kale-Pradhan PB. The Effect of Bariatric Surgery on Hypertension – A Meta Analysis. Ann Pharmacother 2014;48:674-682. DOI: 10.1177/1060028014529260
  13. Lipari M, Benipal H, Kale-Pradhan PB. Roflumilast in the management of chronic obstructive pulmonary disease. Am J Health Syst Pharm. 2013 Dec 1;70(23):2087-95. doi: 10.2146/ajhp130114.
  14. Wilhelm SM, Rjater RG and Kale-Pradhan PB. Perils and Pitfalls of Long-Term Effects of Proton Pump Inhibitors. Expert Rev Clin Pharmacol. 2013 Jul;6(4):443-51. doi: 10.1586/17512433.2013.811206
  15. Kale-Pradhan PB, Zhao JJ, Palmer JR, Wilhelm SM. The role of antimicrobials in Crohn’s disease. Expert Rev. Gastroenterol. Hepatol. 2013;7:281–8. doi: 10.1586/egh.13.6)
  16. Giuliano C, Kale-Pradhan PB, Johnson LB Early response of ceftaroline fosamil in the treatment of soft-tissue infections Expert Rev Clin Pharmacol. 2012;5(5):509-12. doi: 10.1586/ecp.12.50.
  17. Giuliano C, Wilhelm SM, Kale-Pradhan PB. Are Proton Pump Inhibitors Associated with the Development of Community Acquired Pneumonia: A Meta-analysis. Expert Review of Clinical Pharmacology 2012; 5:337-44.
  18. Wilhelm SM, Kale-Pradhan PB. Inflammatory Bowel Disease. In: Richardson M, Chant C, Chessman KH, Finks SW, Hemstreet BA, Hume AL, et al, eds. Pharmacotherapy Self-Assessment Program, 7th ed. Gastroenterology and Nutrition. Lenexa, KS: American College of Clinical Pharmacy. 2012:27-48.
  19. Kale-Pradhan PB, Wilhelm SM and Johnson LB. Clinical Relevance of in vitro Resistance of Echinocandins:A Focus on Candida paripsilosis. Current Fungal Infection Reports 2012;6:107-112 DOI 10.1007/s12281-012-0087-9
  20. Wilhelm SM. and Kale-Pradhan PB. Estimating Creatinine Clearance: A Meta-Analysis. Pharmacotherapy 2011;31(7):658–664.
  21. Wilhelm SM, Johnson JL and Kale-Pradhan PB. Treating bugs with bugs: the role of probiotics as adjunctive therapy for Helicobacter pylori. Annals of Pharmacotherapy 2011;45:960-6.
  22. Kale- Pradhan PB, Wilhelm SM, Johnson LB. Author response to alternative view point use of echinocandins for Candida parapsilosis infections. Pharmacotherapy 2011;31:87e-88e.
  23. Giuliano CA, Dehoorne-Smith ML and Kale-Pradhan PB. Pancreatic Enzyme Products: Digesting the Changes. Annals of Pharmacotherapy 2011;45:658-66.
  24. Kale-Pradhan PB, Morgan G, Wilhelm SM and Johnson LB. A Comparison of the Efficacy of Echinocandins and Non-Echinocandins in the Treatment of Candida parapsilosis: A Meta-Analysis. Pharmacotherapy 2010;30(12):1207–1213.
  25. Wilhelm SM and Kale-Pradhan PB. The effect of arginine and omega 3 fatty acids in critically ill and surgical patients. Expert Rev. Clin. Pharmacol. 2010;3(4):459–469
  26. Kale-Pradhan PB, Jassal H, Wilhelm SM and Cha R. The Role of Lactobacillus in the Prevention of Antibiotic-Associated Diarrhea. Pharmacotherapy 2010;30(2):119–126.
  27. Kale-Pradhan PB and Wilhelm SM. Drug Induced Pancreatitis. In Drug Induced Diseases. James Tisdale and Douglas Miller (eds) 2nd Edition. 2010 American Society of Health System Pharmacists, Bethesda, MD, p 800-818. Major revisions made.